SAN FRANCISCO, CA--(Marketwire - March 12, 2009) - Urigen Pharmaceuticals, Inc. (OTCBB: URGP) (http://www.urigen.com), a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders, has appointed Jeffrey G. Proctor, M.D. to the Company’s Scientific Advisory Board.
“We are pleased to welcome Dr. Proctor to our Scientific Advisory Board,” commented Professor C. Lowell Parsons, M.D., Scientific Founder of Urigen. “Jeff has been intimately involved in both the academic work and clinical trials for Urigen. He has made a number of intellectual contributions to our clinical studies. We are pleased to have him join Professors Mulholland and Stief on our Scientific Advisory Board.”
Dr. Proctor is Director of Interstitial Cystitis at GA Urology, PA in Riverdale, Georgia where he has practiced since November 1997. Dr. Proctor completed his Doctor of Medicine and his Residency in Urology at New York Medical College, Westchester County Medical Center, Valhalla, New York.
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen’s two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen’s URG101, a proprietary combination of approved drugs that is instilled into the bladder, targets painful bladder syndrome, which affects approximately 10.5 million men and women in North America. Urigen’s URG301, a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency, targets acute urgency in females diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. For further information, please visit Urigen’s website at http://www.urigen.com.
Forward-Looking Statement
This press release may contain forward-looking statements. These statements may be identified by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. Urigen has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Urigen believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. Given these risks and uncertainties, investors and security holders are cautioned not to place undue reliance on such forward-looking statements. Urigen does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.
Contact:
Urigen Pharmaceuticals, Inc.
Martin E. Shmagin
Chief Financial Officer
415-781-0350
www.urigen.com
